182 related articles for article (PubMed ID: 26714660)
21. Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Llamas-Velasco M; Cabaleiro T; Solano-López G; Márquez B; Román M; Ochoa D; Talegón M; Daudén E; Abad-Santos F
Pharmacogenomics; 2017 Jan; 18(2):157-164. PubMed ID: 27977334
[TBL] [Abstract][Full Text] [Related]
22. Ustekinumab as therapy for psoriasis in a 2-year-old girl.
Min MS; Shroff A; Rose S; Lebwohl M; Guttman-Yassky E
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e109-e110. PubMed ID: 26377248
[No Abstract] [Full Text] [Related]
23. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
[No Abstract] [Full Text] [Related]
24. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
[No Abstract] [Full Text] [Related]
25. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
Fujita Y; Shinkuma S; Nomura T; Shimizu H
Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
[No Abstract] [Full Text] [Related]
26. Successful treatment of severe psoriasis in an adolescent with ustekinumab.
AbuHilal M; Ho N
Pediatr Dermatol; 2015; 32(3):377-80. PubMed ID: 25727845
[TBL] [Abstract][Full Text] [Related]
27. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
[No Abstract] [Full Text] [Related]
28. Clearance of annular pustular psoriasis with ustekinumab.
Schnabel V; Broekaert SMC; Schön MP; Mössner R
Eur J Dermatol; 2017 Jun; 27(3):296-297. PubMed ID: 28202422
[No Abstract] [Full Text] [Related]
29. Response of superimposed linear psoriasis to ustekinumab: A case report.
Weng HJ; Tsai TF
Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
[No Abstract] [Full Text] [Related]
30. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
[No Abstract] [Full Text] [Related]
31. The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting.
Menting SP; van den Reek JM; Baerveldt EM; de Jong EM; Prens EP; Lecluse LL; Wolbink GJ; Van der Kleij D; Spuls PI; Rispens T
Br J Dermatol; 2015 Sep; 173(3):855-7. PubMed ID: 25865153
[No Abstract] [Full Text] [Related]
32. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
Chiu HY; Chu TW; Cheng YP; Tsai TF
PLoS One; 2015; 10(11):e0142930. PubMed ID: 26566272
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab treatment in patients with psoriasis undergoing hemodialysis.
Umezawa Y; Hayashi M; Kikuchi S; Fukuchi O; Yanaba K; Ito T; Asahina A; Saeki H; Nakagawa H
J Dermatol; 2015 Jul; 42(7):731-4. PubMed ID: 25959602
[TBL] [Abstract][Full Text] [Related]
34. Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study.
Onderdijk AJ; Ijpma AS; Menting SP; Baerveldt EM; Prens EP
Br J Dermatol; 2015 Dec; 173(6):1536-9. PubMed ID: 26134667
[No Abstract] [Full Text] [Related]
35. Efficacy of ustekinumab in palmoplantar pustulosis.
Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Uthurriague C; Paul C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):e204-e206. PubMed ID: 29194805
[No Abstract] [Full Text] [Related]
36. Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy.
Jack C; Mashiko S; Arbour N; Bissonnette R; Sarfati M
Br J Dermatol; 2017 Jul; 177(1):267-270. PubMed ID: 27599204
[No Abstract] [Full Text] [Related]
37. Pregnancy during Ustekinumab Treatment for Severe Psoriasis.
Rocha K; Piccinin MC; Kalache LF; Reichert-Faria A; Silva de Castro CC
Dermatology; 2015; 231(2):103-4. PubMed ID: 25790947
[TBL] [Abstract][Full Text] [Related]
38. Genome-Wide Association Study of Ustekinumab Response in Psoriasis.
Connell WT; Hong J; Liao W
Front Immunol; 2021; 12():815121. PubMed ID: 35154085
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of ustekinumab in a psoriasis patient with human T-cell leukemia/lymphotropic virus type 1 infection.
Kazama M; Umezawa Y; Itoh M; Nobeyama Y; Ito T; Kikuchi S; Yanaba K; Asahina A; Nakagawa H; Ogasawara Y
J Dermatol; 2017 Nov; 44(11):1334-1335. PubMed ID: 27864824
[No Abstract] [Full Text] [Related]
40. Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in a Psoriasis Patient Treated With Ustekinumab.
Dickson L; Menter A
J Drugs Dermatol; 2017 Feb; 16(2):177-179. PubMed ID: 28300862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
